TYK Medicines, Inc
ðŸ‡ðŸ‡°Hong Kong, China
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
Phase 2
Completed
- Conditions
- Leptomeningeal MetastasisNSCLCBrain MetastasesEGFR Activating Mutation
- Interventions
- Drug: TY-9591 Tablets
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 29
- Registration Number
- NCT05146219
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TY-9591 Tablets under Fasted Condition - Arm1Drug: TY-9591 Tablets under Fasted Condition - Arm2Drug: TY-9591 Tablets after a High-fat Meal - Arm1Drug: TY-9591 Tablets after a High-fat Meal - Arm2
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 16
- Registration Number
- NCT04798638
- Locations
- 🇨🇳
Hunan Provincial Tumor Hospital, Changsha, Hunan, China
A Study of TY-302 in Patients With Advanced Solid Tumors
Phase 1
- Conditions
- Solid TumorBreast Cancer
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT04433494
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical Colledge, Beijing, Beijing, China
A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation
Phase 1
Completed
- Conditions
- NSCLC
- Interventions
- Drug: TY-9591(10mg,40mg) qd. po
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 105
- Registration Number
- NCT04204473
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath